Alvotech (ALVO) News Today $11.91 -0.20 (-1.65%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Short Interest in Alvotech (NASDAQ:ALVO) Rises By 47.8%Alvotech (NASDAQ:ALVO - Get Free Report) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 116,800 shares, an increase of 47.8% from the October 31st total of 79,000 shares. Currently, 0.1% of the company's shares are short sold. Based on an average daily volume of 94,800 shares, the short-interest ratio is presently 1.2 days.November 29, 2024 | marketbeat.comNorthland Securities Keeps Their Buy Rating on Alvotech (ALVO)November 25, 2024 | markets.businessinsider.comAlvotech's Position In The Coming Biosimilar Gold RushNovember 21, 2024 | seekingalpha.comAlvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023)November 16, 2024 | finance.yahoo.comAlvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic AdvancementsNovember 16, 2024 | finance.yahoo.comNorthland Securities Reaffirms Their Buy Rating on Alvotech (ALVO)November 16, 2024 | markets.businessinsider.comAlvotech Reports Strong Revenue Growth in 2024November 16, 2024 | markets.businessinsider.comQ3 2024 Alvotech SA Earnings CallNovember 15, 2024 | finance.yahoo.comAlvotech (ALVO) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comAlvotech Showcases Strong Financial Growth and ExpansionNovember 14, 2024 | markets.businessinsider.comBarclays Sticks to Their Buy Rating for Alvotech (ALVO)November 13, 2024 | markets.businessinsider.comAlvotech Reports Financial Results for the First Nine Months of 2024November 13, 2024 | markets.businessinsider.comAlvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024November 7, 2024 | globenewswire.comAlvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024November 7, 2024 | globenewswire.comEMA accepts Alvotech and Advanz Pharma’s AVT05 MAANovember 6, 2024 | msn.comAlvotech announces EMA acceptance of MAA for AVT05November 5, 2024 | markets.businessinsider.comAlvotech’s AVT05 Biosimilar Application Accepted by EMANovember 4, 2024 | markets.businessinsider.comEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)November 4, 2024 | globenewswire.comEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)November 4, 2024 | globenewswire.comAlvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024October 25, 2024 | globenewswire.comAlvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024October 25, 2024 | globenewswire.comAlvotech and Teva Secure FDA Approval for SELARSDIOctober 23, 2024 | markets.businessinsider.comAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)October 22, 2024 | globenewswire.comAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)October 22, 2024 | globenewswire.comAlvotech (ALVO) Gets a Buy from BarclaysOctober 17, 2024 | markets.businessinsider.comSouth Korean company Dong-A ST wins FDA approval for Stelara biosimilarOctober 12, 2024 | msn.comEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®October 10, 2024 | globenewswire.comEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®October 10, 2024 | globenewswire.comAlvotech (NASDAQ:ALVO) Shares Sold by Marshall Wace LLPMarshall Wace LLP reduced its position in Alvotech (NASDAQ:ALVO - Free Report) by 84.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 38,992 shares of the company's stock after selling 211,131 shares during the period. Marshall Wace LLP owned about 0.12% of AlOctober 10, 2024 | marketbeat.comAlvotech (NASDAQ:ALVO) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comAlvotech (ALVO) Shares Up 3.77% on Oct 2October 2, 2024 | gurufocus.comFresenius Kabi wins FDA approval for Stelara biosimilar OtulfiOctober 2, 2024 | msn.comAlvotech (NASDAQ:ALVO) Shares Sold by Sculptor Capital LPSculptor Capital LP lowered its stake in Alvotech (NASDAQ:ALVO - Free Report) by 51.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 945,098 shares of the company's stock after selling 1,001,064 shares during the quartSeptember 27, 2024 | marketbeat.comAlvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®September 25, 2024 | globenewswire.comAlvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®September 25, 2024 | globenewswire.comAlvotech (NASDAQ:ALVO) Short Interest Up 108.1% in AugustAlvotech (NASDAQ:ALVO - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 135,900 shares, a growth of 108.1% from the July 31st total of 65,300 shares. Based on an average trading volume of 131,500 shares, the short-interest ratio is presently 1.0 days. Approximately 0.1% of the shares of the stock are sold short.August 28, 2024 | marketbeat.comAlvotech: Steady Progress Offers A Good Chance Of UpsideAugust 26, 2024 | seekingalpha.comAlvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 26, 2024 | globenewswire.comAlvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 26, 2024 | globenewswire.comAlvotech (ALVO.IC)August 22, 2024 | uk.finance.yahoo.comAlvotech Second Quarter 2024 Earnings: EPS: US$0.25 (vs US$0.83 in 2Q 2023)August 20, 2024 | finance.yahoo.comAlvotech’s Strong Q2 Performance and Positive Outlook Justify Buy RatingAugust 18, 2024 | markets.businessinsider.comAlvotech (NASDAQ:ALVO) Issues Earnings Results, Beats Estimates By $0.56 EPSAlvotech (NASDAQ:ALVO - Get Free Report) announced its earnings results on Thursday. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.56. The company had revenue of $198.75 million for the quarter. During the same quarter in the previous year, the firm earned ($0.43) earnings per share.August 18, 2024 | marketbeat.comQ2 2024 Alvotech SA Earnings Call TranscriptAugust 17, 2024 | gurufocus.comAlvotech (ALVO) Q2 2024 Earnings Call Transcript Highlights: Record Revenues and Positive EBITDAAugust 17, 2024 | gurufocus.comAlvotech's (NASDAQ:ALVO) biggest owners are private equity firms who got richer after stock soared 19% last weekAugust 17, 2024 | finance.yahoo.comAlvotech (NASDAQ:ALVO) Sees Large Decrease in Short InterestAlvotech (NASDAQ:ALVO - Get Free Report) was the target of a large drop in short interest in July. As of July 31st, there was short interest totalling 65,300 shares, a drop of 11.5% from the July 15th total of 73,800 shares. Based on an average daily volume of 115,100 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.1% of the shares of the stock are sold short.August 17, 2024 | marketbeat.comH&R Block Shares Surge 10% on Profit and Dividend Boost, Applied Materials Drops 3% Despite Strong Earnings, Latest in EarningsAugust 16, 2024 | msn.comAlvotech (ALVO) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comUK economy grows 0.6% between April and JuneAugust 16, 2024 | uk.finance.yahoo.com Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now ALVO Media Mentions By Week ALVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALVO News Sentiment▼1.000.60▲Average Medical News Sentiment ALVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALVO Articles This Week▼03▲ALVO Articles Average Week Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCTXW News Today ENGNW News Today FBIOP News Today GOVXW News Today PHVS News Today RCKTW News Today SNDL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALVO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
